The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Respiration

• Publication date

  2011-01-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000322843PMID 21242665
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular Pathology of Non-Small Cell Lung Cancer.

  2012cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• EGFR testing in lung cancer is ready for prime time.

  2009cited by this paper
• Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST Study

  2008cited by this paper
• Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib

  2008cited by this paper
• A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

  2008cited by this paper
• MDR1 Single Nucleotide Polymorphism G2677T/A and Haplotype Are Correlated with Response to Docetaxel-Cisplatin Chemotherapy in Patients with Non-Small-Cell Lung Cancer

  2008cited by this paper
• Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

  2008cited by this paper
• Molecular Predictors of EGFR-TKI Sensitivity in Advanced Non–small Cell Lung Cancer

  2008cited by this paper
• Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

  2007cited by this paper
• The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non–small Cell Lung Cancer

  2007cited by this paper
• The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.

  2006cited by this paper
• Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

  2006cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer

  2006cited by this paper
• Erlotinib in lung cancer - molecular and clinical predictors of outcome.

  2005cited by this paper
• Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

  2005cited by this paper
• Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

  2005cited by this paper
• Molecular Pathology of Non-Small-Cell Lung Cancer

  2005cited by this paper
• Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  2004cited by this paper

• A Framework for Lung Cancer Detection at Early Stages with IoT and Decision Support System

  2023cites this paper
• The role of lactate deshydrogenase levels on non-small cell lung cancer prognosis: a meta-analysis.

  2019cites this paper
• Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

  2017cites this paper
• Decision support systems for incurable non-small cell lung cancer: a systematic review

  2017cites this paper
• Weekly Low Dose Pemetrexed for an Elderly Advanced Lung Adenocarcinoma Patient Who had Failed First-Line Chemotherapy and EGFR-TKIs: A Case Report

  2016cites this paper
• Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools

  2015cites this paper
• Pulmonary function parameters as prognostic factors in advanced non-small cell lung cancer.

  2014cites this paper
• Differences in Plasma MMPs and TIMPs Protein Expression and Chemotherapy Response in Patients with Tobacco- or Wood-Smoke-Induced Lung Cancer

  2012cites this paper
• The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors

  2012cites this paper
• Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I–IV Non-Small Cell Lung Cancer Patients

  2012cites this paper